• Morgan Health, CVS Health Ventures, and Humana, alongside other strategic payers and providers, invest in Thyme Care at a valuation of more than $2B
  
  
• The new capital accelerates Thyme Care's continued growth and establishes Thyme Companies, a newly formed parent entity building a broader portfolio of businesses to tackle distinct parts of the oncology journey

NASHVILLE, Tenn., Sept. 2, 2026 /PRNewswire/ -- Thyme Care, the nationally recognized oncology company, today announced a new Series E financing round of over $125M. Morgan Health led the round, with participation from strategic healthcare investors Humana and CVS Health Ventures, as well as institutional investors AlleyCorp, HealthQuest Capital, Foresite Capital, Concord Health Partners, Frist Cressey Ventures, Town Hall Ventures, and a16z Bio + Health.

The financing brings together strategic investors from across the cancer care ecosystem, including the largest national payers, community oncology, health systems, and leaders in employer-sponsored health care, reflecting favorable investor outlook on Thyme Care's care model and its potential to take on the broader challenges in cancer care. Today, Thyme Care services are available to more than 10.5 million people across all 50 states, and the company manages more than $7 billion in oncology spend. By aligning care around the patient, the model delivers 5 to 10 percent validated reductions in total cost of care, creating measurable value for patients, providers, and health plan partners. Supported by strong financial discipline, Thyme Care is profitable, generates meaningful positive free cash flow, and is positioned to accelerate its next phase of growth.

"People living with cancer have traditionally been left to coordinate care themselves and pay more along the way. Thyme Care is changing that experience and making it possible to improve cancer care while lowering costs," said Dan Mendelson, chief executive officer of Morgan Health. "We're continuing to invest in Thyme Care because we're confident they can continue to deliver value to patients and payers – as they make the next wave of cancer care innovation easier to access and navigate."

Alongside the Series E, Thyme Care is establishing Thyme Companies, a newly formed parent entity designed to build a portfolio of new, independent businesses in oncology that address persistent barriers to better cancer care. Grounded in data, enabled by technology, and built on trusted partnerships, Thyme Companies is positioned to take on oncology's biggest challenges. Areas under active development include accelerating the adoption of lower-cost biosimilars and improving clinical trial accrual, where slow enrollment limits patient access to beneficial trials and slows drug development. The first of these businesses is expected to launch later this year.

To support this next phase of growth, Thyme Care co-founder Robin Shah will serve as executive chairman of Thyme Companies leading the strategy and development of new businesses and working closely with his co-founder Bobby Green, M.D. to bring the connected, patient-first approach that built Thyme Care, to a broader set of healthcare challenges. Thyme Care continues under CEO Brad Diephuis, M.D., with Dr. Green as president and chief medical officer. Thyme Care remains the anchor of the Thyme Companies family of businesses; its name, partnerships, and member experience unchanged.

"When we founded Thyme Care, our vision was never limited to one part of cancer care. We wanted to create a better oncology care system," says Shah. "Thyme Care showed it could be done, and as we've grown alongside patients, providers and health plans, we've gained a deep perspective on the challenges that get in the way of better care. Thyme Companies is the next step in this journey, enabling us to build new solutions fully informed by what we've learned, while continuing to invest in the core business that made it possible."

About Thyme Companies
Thyme Companies is the parent of the Thyme family of businesses, focused on building companies against the disconnection in how cancer care is delivered, accessed and paid for. Anchored by Thyme Care, the nationally recognized oncology care company, Thyme Companies develops independent businesses connected by one mission: to transform the experience of cancer for the people living through it. To learn more, visit thymecompanies.com.

About Thyme Care
Thyme Care aligns accountability across the cancer care journey, coordinating patients, providers, and health plans around a shared model of care that drives better outcomes and lower costs for everyone. Through dedicated care teams and technology, Thyme Care integrates directly into existing workflows to support patients longitudinally, close gaps between visits, and align clinical decisions with financial accountability. To learn more, visit thymecare.com.

Inkhouse for Thyme Care
thymecare@inkhouse.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/thyme-care-closes-125-million-series-e-establishes-thyme-companies-to-broaden-its-impact-across-the-oncology-ecosystem-302867835.html

SOURCE Thyme Care